- Melatonin is produced in the gut as well as the brain, and early research suggests it may influence gut motility and pain perception in IBS — but the evidence is still preliminary.
- Small clinical trials show modest reductions in abdominal pain and bloating in some IBS patients, though study quality is generally low and effect sizes are inconsistent.
- Doses used in IBS research (3–6 mg at bedtime) differ from typical sleep doses, and optimal timing and duration remain unclear.
- Melatonin is not a proven IBS treatment; lifestyle, dietary changes, and established therapies should remain the foundation of IBS management.
What the evidence shows
The honest answer is: the evidence is intriguing but weak. There are a handful of small randomized controlled trials (RCTs), but most enroll fewer than 60 participants, run for only four to eight weeks, and do not always use validated IBS outcome measures. That makes it hard to draw firm conclusions.
The most-cited trial is by Song et al. (2005), who randomized 17 IBS patients to 3 mg melatonin or placebo at bedtime for two weeks. The melatonin group reported a statistically significant reduction in abdominal pain scores compared with placebo, with no meaningful effect on stool frequency or consistency (Song et al., 2005). A follow-up study by the same group expanded the sample to 40 patients over eight weeks and again found a significant pain benefit, alongside improved rectal pain thresholds during distension testing — suggesting a visceral analgesic effect rather than simply a sleep improvement (Lu et al., 2005).
A 2014 review by Siah et al. surveyed the published trials and concluded that melatonin appeared to reduce abdominal pain in IBS, particularly in patients who also had disrupted sleep, but noted that study heterogeneity, small sample sizes, and short follow-up periods prevented any definitive recommendation (Siah et al., 2014). Importantly, most studies did not find consistent improvement in bloating, diarrhea, or constipation — so pain may be the only symptom where a signal exists, and even that signal is modest.
There are no large, well-powered RCTs, no head-to-head comparisons with established IBS therapies (such as low-FODMAP diet or antispasmodics), and no long-term safety data in this population. The evidence base is thin enough that major gastroenterology guidelines do not currently recommend melatonin for IBS.
How it works (mechanism)
The gut contains roughly 400 times more melatonin than the pineal gland, and the gastrointestinal tract synthesizes its own supply independently of the brain (Bubenik, 2002). Melatonin receptors (MT1 and MT2) are expressed throughout the gut wall, where they appear to modulate:
- Smooth muscle tone — influencing how quickly or slowly contents move through the bowel.
- Visceral sensitivity — animal and human distension studies suggest melatonin may raise the pain threshold in the colon, which is relevant because IBS is partly a disorder of heightened visceral perception.
- Gut-brain axis signaling — melatonin may interact with serotonin pathways; roughly 95% of the body's serotonin is in the gut and plays a key role in IBS symptom generation.
- Local anti-inflammatory effects — some cell studies suggest melatonin can reduce oxidative stress and cytokine release in intestinal tissue, though this has not been confirmed in human IBS trials.
The biological rationale is plausible. Plausibility, however, is not the same as proof — many supplements with sound mechanisms fail to show benefit in well-designed human trials.
Dose & timing if you try it
If you and your doctor decide to trial melatonin for IBS symptoms, here is what the published research used:
- Dose: 3 mg per night. One study used 6 mg, but higher doses were not clearly more effective and increased the risk of next-day grogginess.
- Timing: 30 minutes before bedtime. Most trials dosed at night, partly because melatonin's half-life is short (around 45 minutes) and nocturnal dosing aligns with its natural secretion rhythm.
- Duration: Trials ran four to eight weeks. There is no data on whether benefits persist beyond this window or whether continuing beyond a few months is safe or useful.
- Form: Immediate-release tablets were used in research. Extended-release formulations have not been tested specifically in IBS populations.
Keep a symptom diary before and during any trial so you can objectively judge whether anything changes — the placebo response in IBS trials is notoriously high (often 30–40%), and self-assessment without a baseline is unreliable.
Who should skip
- Pregnant and breastfeeding individuals: Safety data in pregnancy is lacking; melatonin crosses the placenta and is present in breast milk. Avoid unless specifically directed by an obstetrician.
- Children and adolescents: Not studied for IBS in this age group; pediatric melatonin use should always involve a pediatrician.
- People taking anticoagulants (e.g., warfarin): Melatonin may have additive effects on bleeding risk (Siah et al., 2014). Discuss with your prescriber.
- People taking fluvoxamine or other strong CYP1A2 inhibitors: These drugs can substantially raise melatonin blood levels, increasing side-effect risk.
- People with autoimmune conditions: Melatonin has immunomodulatory properties; the clinical relevance is uncertain but warrants caution.
- Anyone with daytime sedation concerns: Even low-dose melatonin can impair alertness in some individuals; avoid if you drive early in the morning.
Bottom line
Melatonin has a credible biological reason to influence gut function, and small studies hint at a modest reduction in IBS-related abdominal pain — particularly in patients whose IBS and sleep disturbance overlap. But the trials are too small, too short, and too inconsistent to call this a proven therapy. It is not a treatment for IBS.
If you have IBS, your highest-yield options remain: a low-FODMAP elimination diet (supported by multiple large RCTs), gut-directed cognitive behavioral therapy, and — where appropriate — medications your gastroenterologist recommends. Melatonin might be a reasonable add-on conversation with your doctor if sleep disruption is part of your picture, but it should not replace any of the above, and you should not expect dramatic symptom relief.
References
- Bubenik, G.A. (2002). Gastrointestinal melatonin: Localization, function, and clinical relevance. Digestive Diseases and Sciences, 47(10), 2336–2348.
- Lu, W.Z., Gwee, K.A., Moochhalla, S., & Ho, K.Y. (2005). Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: A double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 22(10), 927–934.
- Siah, K.T., Wong, R.K., & Ho, K.Y. (2014). Melatonin for the treatment of irritable bowel syndrome. World Journal of Gastroenterology, 20(10), 2492–2498.
- Song, G.H., Leng, P.H., Gwee, K.A., Moochhalla, S., & Ho, K.Y. (2005). Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: A randomised, double blind, placebo controlled study. Gut, 54(10), 1402–1407.
Overall evidence rating: Low. High-quality large trials are lacking. This area warrants further research before clinical recommendations can be made.
```